|
WO2020188015A1
|
|
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
WO2020127965A1
|
|
New conjugated nucleic acid molecules and their uses
|
|
EP3765613A1
|
|
A dbait molecule against acquired resistance in the treatment of cancer
|
|
WO2019002614A1
|
|
New oral formulations of belinostat
|
|
CA3067723A1
|
|
New oral formulations of belinostat
|
|
WO2018162439A1
|
|
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
EP3461480A1
|
|
Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
|
|
EP3461488A1
|
|
Combination of a dbait molecule and a hdac inhibitor for treating cancer
|
|
WO2017186882A1
|
|
A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
|
|
KR20180118716A
|
|
Treatment of cancer by systemic administration of DBAIT molecules
|
|
WO2017144543A1
|
|
Combination therapies comprising immuno-oncology agents and belinostat
|
|
WO2017046037A1
|
|
Nanoparticles loaded with active ingredients, their process of preparation and their uses
|
|
HUE037926T2
|
|
Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
|
